Clinical Trial Detail

NCT ID NCT01334502
Title Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors North Central Cancer Treatment Group
Indications

diffuse large B-cell lymphoma

Therapies

Everolimus

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine

Age Groups: adult

No variant requirements are available.